ORCHARD THERAPEUTICS PLC-ADR (ORTX)
US68570P2002 - ADR
ORCHARD THERAPEUTICS PLC-ADR
NASDAQ:ORTX (1/23/2024, 7:00:02 PM)
16.7
+0.05 (+0.3%)
Company Profile
Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The firm is engaged in transforming the lives of people affected by rare diseases through the development of curative gene therapies. Its ex vivo autologous hematopoietic stem cell (HSC), gene therapy approach harnesses the power of genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. Its ex vivo autologous HSC gene therapy approach seeks to transform a patient’s autologous HSCs into a gene-modified cellular drug product to treat the patient’s disease. Its lead program is OTL-200 operates under the brand name Libmeldy for eligible patients with early-onset metachromatic leukodystrophy (MLD). Its programs in immunological disorders consist of two pre-clinical programs, OTL-104 for Crohn’s disease with mutations in the nucleotide-binding oligomerization domain-containing protein 2 (NOD2-CD), and OTL-105 for hereditary angioedema (HAE).
Company Info
ORCHARD THERAPEUTICS PLC-ADR
245 Hammersmith Road, 3Rd Floor
London EC4N 6EU
P: 114402033846700
CEO: Bobby Gaspar
Employees: 166
Website: https://www.orchard-tx.com/
ORTX News
a month ago - Orchard Therapeutics (Europe) LimitedOrchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic LeukodystrophyFive specialized treatment centers being qualified across the U.S. to minimize travel burden on eligible patients and their families Orchard Assist...
a month ago - Orchard Therapeutics (Europe) LimitedOrchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.One-time treatment with Lenmeldy has shown the potential to restore enzymatic function to stop or slow disease progression, with up to 12 years of follow-up (median 6.76 years)
One-time treatment with Lenmeldy has shown the potential to restore enzymatic function to stop or slow disease progression, with up to 12 years of follow-up (median 6.76 years)
3 months ago - Orchard Therapeutics (Europe) LimitedOrchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler SyndromeGene therapy being developed as a one-time treatment to address the underlying cause of the disease by inserting a functional copy of the human IDUA gene...
ORTX Twits
Here you can normally see the latest stock twits on ORTX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
